Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) |
Chronic Pruritus of Unknown Origin | Phase3 | Argentina Canada Japan South Korea United States View all |
NCT07700056 |
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. |
Asthma | Phase3 | Argentina France Hungary Poland Romania Slovakia South Africa Spain Taiwan View all |
NCT05776927 |
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS |
Hidradenitis Suppurativa | Phase3 | Argentina Australia Canada China France Germany Malaysia Spain United States View all |
NCT07665437 |
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) | Phase3 | Argentina Australia Austria Belgium Brazil Canada China Czechia France Germany India Italy Japan Malaysia Netherlands Poland South Korea Spain Switzerland Taiwan Turkey (Türkiye) United States View all |
NCT07357727 |
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo |
Non-segmental Vitiligo | Phase2 | Argentina Australia Canada China France Germany India Italy Japan Netherlands Spain United States View all |
NCT07431177 |
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease |
Huntington Disease | Phase3 | Argentina Australia Belgium Bulgaria Canada China Colombia Czechia Denmark France Germany Hungary Israel Italy Japan Netherlands Poland Portugal Romania Saudi Arabia Slovakia South Korea Spain Switzerland Taiwan United Kingdom United States View all |
NCT07326709 |
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration |
Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase2 | Argentina Australia Brazil Bulgaria Canada Colombia Czechia France Germany Hungary Italy Japan Poland Puerto Rico Romania Spain United Kingdom United States View all |
NCT07441642 |
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis |
Secondary Progressive Multiple Sclerosis (SPMS) | Phase3 | Argentina Australia Austria Belgium Brazil Bulgaria Canada China Colombia Croatia Czechia Denmark Estonia France Germany Greece Hungary India Ireland Israel Italy Latvia Lithuania Mexico Netherlands Poland Portugal Romania Slovakia Slovenia South Africa Spain Sweden Switzerland United Kingdom United States View all |
NCT07225504 |
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN |
Primary Immunoglobulin A Nephropathy (IgAN) | Phase3 | Argentina Australia China Hong Kong Israel Japan Saudi Arabia United States View all |
NCT06994845 |
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. |
Relapsing Multiple Sclerosis | Phase3 | Argentina Australia Belgium Brazil Canada Czechia Denmark France Germany Greece Italy Mexico Portugal Slovakia South Africa Spain Switzerland United Kingdom United States View all |
NCT06846281 |